Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.02T | 35.2x | 1.18 | ₹1,670 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹3.87T | 33.9x | 1.18 | ₹1,608.95 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.6% Upside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.51T | 72.4x | 1.45 | ₹5,675 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.48T | 72x | 1.45 | ₹5,583 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.18T | 23.7x | 0.68 | ₹1,469.40 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.2% Upside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.17T | 23.5x | 0.68 | ₹1,453 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.05T | 55.9x | 2.27 | ₹3,092 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.04T | 56x | 2.27 | ₹3,092.30 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | BSE | Healthcare | Healthcare Providers & Services | ₹956.20B | 103x | -18.99 | ₹986.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | NSE | Healthcare | Healthcare Providers & Services | ₹956.20B | 103x | -18.99 | ₹989.75 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹937.95B | 17.7x | 6.57 | ₹1,126.15 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.6% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹930.89B | 32.2x | 0.54 | ₹2,043.25 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹921.29B | 17.1x | 6.57 | ₹1,107.95 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹911.88B | 48.3x | 2.61 | ₹2,165 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.5% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹911.88B | 48.3x | 2.61 | ₹2,166.45 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.5% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹896.65B | 31.1x | 0.54 | ₹1,965 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | NSE | Healthcare | Pharmaceuticals | ₹894.49B | 19.6x | 0.38 | ₹888.25 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.7% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹894.49B | 19.6x | 0.38 | ₹889.50 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.7% Upside | Upgrade to Pro+ | |
Apollo Hospitals | NSE | Healthcare | Healthcare Providers & Services | ₹882.84B | 67.2x | 1.03 | ₹6,143.75 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
Apollo Hospitals | BSE | Healthcare | Healthcare Providers & Services | ₹882.84B | 67.2x | 1.03 | ₹6,141.10 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.7% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹644.11B | 18.3x | 0.69 | ₹1,104.55 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.8% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹634.70B | 18.4x | 0.69 | ₹1,095.65 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹631.77B | 47.8x | 2.97 | ₹29,795.85 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.5% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹631.77B | 47.8x | 2.97 | ₹29,700 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹567.67B | 26.3x | 0.71 | ₹4,750 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹559.96B | 26.2x | 0.71 | ₹4,679.25 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.6% Upside | Upgrade to Pro+ | |
Fortis Healthcare | NSE | Healthcare | Healthcare Providers & Services | ₹464.45B | 60.3x | 1.59 | ₹615.55 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
Fortis Healthcare | BSE | Healthcare | Healthcare Providers & Services | ₹464.45B | 60.3x | 1.59 | ₹606 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹462.97B | 54.2x | 0.87 | ₹2,730.35 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.2% Downside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹454.56B | 53.2x | 0.87 | ₹2,691.85 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.9% Downside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹400.69B | -226.9x | -2.63 | ₹1,419.10 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
Biocon | NSE | Healthcare | Biotechnology & Medical Research | ₹398.60B | 50x | -1.5 | ₹333.40 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.9% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹395.19B | -226.7x | -2.63 | ₹1,401.70 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
Biocon | BSE | Healthcare | Biotechnology & Medical Research | ₹388.96B | 48.2x | -1.5 | ₹325.45 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.6% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹339.72B | 46.8x | 1.59 | ₹1,339 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.4% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹334.75B | 45.6x | 1.59 | ₹1,313.20 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.7% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹321.40B | 36.3x | 1.54 | ₹2,560.50 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26% Upside | Upgrade to Pro+ | |
Narayana Hrudayalaya | BSE | Healthcare | Healthcare Providers & Services | ₹319.67B | 40.8x | 26.3 | ₹1,576 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.9% Downside | Upgrade to Pro+ | |
Narayana Hrudayalaya | NSE | Healthcare | Healthcare Providers & Services | ₹319.67B | 40.8x | 26.3 | ₹1,573.20 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.9% Downside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹318.02B | 35.3x | 1.54 | ₹2,541 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.3% Upside | Upgrade to Pro+ | |
Global Health | BSE | Healthcare | Healthcare Providers & Services | ₹315.46B | 61.1x | 5.32 | ₹1,170.85 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Global Health | NSE | Healthcare | Healthcare Providers & Services | ₹315.46B | 61.1x | 5.32 | ₹1,168.30 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
Laurus Labs | BSE | Healthcare | Pharmaceuticals | ₹314.87B | 157.1x | 23.23 | ₹584.35 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -12% Downside | Upgrade to Pro+ | |
Laurus Labs | NSE | Healthcare | Pharmaceuticals | ₹314.87B | 157.1x | 23.23 | ₹584.35 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -12% Downside | Upgrade to Pro+ | |
Suven Pharma | BSE | Healthcare | Pharmaceuticals | ₹294.63B | 102.4x | -4.26 | ₹1,160 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.8% Upside | Upgrade to Pro+ | |
Suven Pharma | NSE | Healthcare | Pharmaceuticals | ₹294.63B | 102.4x | -4.26 | ₹1,157.95 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.8% Upside | Upgrade to Pro+ | |
Syngene International Ltd BO | BSE | Healthcare | Biotechnology & Medical Research | ₹271.36B | 54.2x | ₹676.10 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.1% Upside | Upgrade to Pro+ | ||
Syngene International Ltd | NSE | Healthcare | Biotechnology & Medical Research | ₹269.48B | 54.8x | ₹671.80 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.5% Upside | Upgrade to Pro+ | ||
Piramal Pharma | BSE | Healthcare | Pharmaceuticals | ₹267.02B | 719.4x | 3.32 | ₹201.25 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Piramal Pharma | NSE | Healthcare | Pharmaceuticals | ₹267.02B | 719.4x | 3.32 | ₹201.82 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |